Alto Neuroscience, Inc. — insider transactions
9 transactions on record · ANRO · CIK 1999480
Aggregates
computed from the filings belowPurchases, 12m
0
count of open-market buys
Sales, 12m
9
count of open-market sales
Buy / sell ratio, 12m
0.00
purchases per sale
Distinct insiders, 12m
1
Bought, 3m
$0
Sold, 3m
$3.9M
Median disclosure lag
2.0 d
trade date to filing date
Largest single trade, 24m
$2.9M
2026-09-29
Director share, 12m
0.0%
of transactions where role is stated
Current run
9 sells
consecutive same-direction transactions
Net 3m flow
-$3.9M
purchases minus sales
Total on record
9
Transactions
9 most recent shown| Disclosed | Traded | Lag, d | Insider | Role | Transaction | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-01 | 2026-09-29 | 2 | Smith Nicholas Conrad | PRESIDENT AND CFO | Open market sale | 110,830 | $26.58 | $2.9M | filing |
| 2026-10-01 | 2026-09-30 | 1 | Smith Nicholas Conrad | PRESIDENT AND CFO | Open market sale | 886 | $26.87 | $23.8K | filing |
| 2026-10-01 | 2026-09-30 | 1 | Smith Nicholas Conrad | PRESIDENT AND CFO | Exercise of derivative | 24,056 | $0.00 | — | filing |
| 2026-10-01 | 2026-09-29 | 2 | Smith Nicholas Conrad | PRESIDENT AND CFO | Exercise of derivative | 54,375 | $2.35 | $127.8K | filing |
| 2026-10-01 | 2026-09-30 | 1 | Smith Nicholas Conrad | PRESIDENT AND CFO | Open market sale | 23,170 | $25.78 | $597.3K | filing |
| 2026-10-01 | 2026-09-29 | 2 | Smith Nicholas Conrad | PRESIDENT AND CFO | Exercise of derivative | 54,375 | $0.00 | — | filing |
| 2026-10-01 | 2026-09-29 | 2 | Smith Nicholas Conrad | PRESIDENT AND CFO | Exercise of derivative | 56,455 | $2.35 | $132.7K | filing |
| 2026-10-01 | 2026-09-30 | 1 | Smith Nicholas Conrad | PRESIDENT AND CFO | Exercise of derivative | 24,056 | $2.35 | $56.5K | filing |
| 2026-10-01 | 2026-09-29 | 2 | Smith Nicholas Conrad | PRESIDENT AND CFO | Exercise of derivative | 56,455 | $0.00 | — | filing |